Imprimis Pharmaceuticals Signs Agreement with Specialty Pharmacy Division of One of the Nation's Largest Pharmacy Benefit Managers

SAN DIEGO, Nov. 10, 2016

1. The Imprimis Cares® formulary will be made available through the specialty pharmacy division of the PBM, which includes more than 65 million covered lives.
2. Imprimis will supply all formulations included under its Imprimis Cares® formulary including the patent-pending tiopronin delayed-release formulations, a lower cost alternative to Thiola®; pyrimethamine and leucovorin formulations, an alternative to Daraprim®; the company's proprietary Dropless Therapy® injectable and LessDrops® topical formulations; as well as additional compounded drug formulations for patient populations that may not have available alternatives to increasingly expensive branded medications and lacking meaningful generic competition.
3. Prescription orders will flow through Imprimis' MaxRx Prescriber Portal™, allowing for customer ordering and tracking ease.
4. Both parties shall ensure that patients continue to receive expert personalized support needed to manage their specific conditions.

Mark L. Baum, CEO of Imprimis, stated, "Healthcare payors in the U.S. and their patients are concerned about the rising costs of prescription drugs.  This agreement represents a new approach to more efficiently deliver medications from the manufacturer directly to the consumer, thereby eliminating several layers of inefficiencies for the tens of millions of Americans whose prescription drug benefits are managed by this renowned PBM.  We believe this new model is going to drive down costs significantly for our partner's insurance company customers, and that other payors we are working with will see this as a viable approach to lower costs while providing patients with safe, high quality, innovative solutions."

"We expect our state-of-the-art New Jersey facility, which we recently registered with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility, will play an important role as we begin to dispense our Imprimis Cares formulary under this new relationship.  We also look forward to expanding into new markets in which our partners seek solutions," Mr. Baum concluded.

Imprimis' Commitment to High Quality Affordable Medications

Imprimis is committed to the company's vision of providing patients with affordable access to the medications they need.  The company intends to continue to expand its Imprimis Cares formulary and introduce additional drug formulations for patient populations that may not have available alternatives to increasingly expensive branded medications.  Imprimis is dedicated to providing high quality compounded medications made from FDA-approved ingredients produced at FDA-inspected and PCAB-accredited facilities.  Federal and state oversight is a part of every aspect of the Imprimis drug supply chain from raw material acquisition to production, testing and dispensing.  For additional information, please visit http://www.imprimisrx.com/why-imprimisrx/quality/.  

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative compounded medications in all 50 states.  The company's unique business model drives patient access and affordability to many critical medicines.  Headquartered in San Diego, California, Imprimis owns and operates three dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.